Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Amortization of Deferred Charges of $604000.0 for Q2 2026, up 62.8% year-over-year from $371000.0 in Q2 2025, and up 34.52% quarter-over-quarter from $449000.0 in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Amortization of Deferred Charges for 5 consecutive years, with $604000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortization of Deferred Charges rose 62.8% year-over-year to $604000.0; the TTM figure through Jun 2026 stood at $1.8 million (up 4.58% YoY), while the FY2025 annual figure was $1.6 million, down 23.22% from the prior year.
- Amortization of Deferred Charges improved to $604000.0 in Q2 2026 per MDGL's latest filing, from $449000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $753000.0 in Q4 2023 and bottomed at $178000.0 in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $468058.8 across 5 years, with a median of $468000.0 in 2025.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges soared 211.24% — and 2024, when it tumbled 35.99%.
- Madrigal Pharmaceuticals' Amortization of Deferred Charges stood at $306000.0 in 2022, then surged by 146.08% to $753000.0 in 2023, then sank by 35.99% to $482000.0 in 2024, then retreated by 2.9% to $468000.0 in 2025, then increased by 29.06% to $604000.0 in 2026.
- Business Quant data shows MDGL's Amortization of Deferred Charges at $604000.0 in Q2 2026, $449000.0 in Q1 2026, and $468000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 464,000.00 |
| Mar 31, 2026 | 449,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Dec 31, 2024 | 482,000.00 |
| Sep 30, 2024 | 480,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Mar 31, 2024 | 655,000.00 |
| Dec 31, 2023 | 753,000.00 |
| Sep 30, 2023 | 674,000.00 |
| Jun 30, 2023 | 554,000.00 |
| Mar 31, 2023 | 433,000.00 |
| Dec 31, 2022 | 306,000.00 |
| Sep 30, 2022 | 313,000.00 |
| Jun 30, 2022 | 178,000.00 |